PCI Biotech announced that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Amphinex. Amphinex is in development as a new local treatment for recurrent head and neck cancer and the phase II program has already been initiated in Europe.